Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function
- 1 October 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 14 (5) , 459-468
- https://doi.org/10.1097/00041433-200310000-00006
Abstract
This review focuses on recent advances on the roles of peroxisome proliferator-activated receptors in the control of lipid metabolism, and the inflammatory response of macrophages and the potential participation of these actions in the modulation of atherogenesis. Altered macrophage functions contribute to the pathogenesis of many infectious, immunological and inflammatory disease processes. Pharmacological modulation of macrophage gene expression therefore represents an important strategy for the prevention and treatment of inflammation-related diseases, such as atherosclerosis. Peroxisome proliferator-activated receptors are lipid-activated transcription factors that control lipid and lipoprotein metabolism, glucose and energy homeostasis, as well as cellular differentiation and proliferation. Recent data suggest that peroxisome proliferator-activated receptor α and peroxisome proliferator-activated receptor γ activators may decrease the incidence of cardiovascular disease, not only by correcting metabolic disorders, but also by directly acting at the level of the vascular wall. In this context, ligand-activated peroxisome proliferator-activated receptors control cellular functions by regulating gene expression in different cell types, including monocytes, macrophages and foam cells. These findings identify the crucial roles of peroxisome proliferator-activated receptors in macrophages, improving the comprehension of the patho-physiological mechanisms of atherogenesis. Moreover, a scientific rationale for the evaluation of peroxisome proliferator-activated receptor activators in the treatment of inflammatory disorders such as atherosclerosis is thus provided.Keywords
This publication has 63 references indexed in Scilit:
- The role of PPARs in atherosclerosisTrends in Molecular Medicine, 2002
- Ciglitazone Inhibits Plasmin-Induced Proinflammatory Monocyte Activation via Modulation of p38 MAP Kinase ActivityThrombosis and Haemostasis, 2002
- Peroxisome proliferator-activated receptors: from transcriptional control to clinical practiceCurrent Opinion in Lipidology, 2001
- Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammationInflammation Research, 2000
- Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator–activated receptor γJournal of Clinical Investigation, 2000
- Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytesEuropean Journal of Pharmacology, 2000
- Peroxisome Proliferator-Activated Receptor-γ Activators Inhibit IFN-γ-Induced Expression of the T Cell-Active CXC Chemokines IP-10, Mig, and I-TAC in Human Endothelial CellsThe Journal of Immunology, 2000
- Thiazolidinedione inhibits the production of monocyte chemoattractant protein‐1 in cytokine‐treated human vascular endothelial cellsFEBS Letters, 1999
- PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial CellsCirculation, 1999
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999